Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:

Recent Articles

Week in Review: Foreseen Sells ADC Rights to France's Ipsen in $1 Billion Deal
Sichuan Biokin, Parent of SystImmune, Plans $500 Million IPO in Hong Kong
Keymed Bio Out-licenses Global Rights for Two Bispecifics in $186 Million Deal
Foreseen Bio Out-Licenses Novel ADC to Ipsen in $1 Billion Agreement
Sanyou Bio Adds BioGeometry’s AI Antibody Design to its CRO Services
ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital